Dawnrays Pharmaceutical Holdings Ltd. operates as an investment holding company, which engages in the development, manufacturing and selling of cephalosporin antibiotics, and various system specific medicines. It operates through the following business segments: Intermediates & Bulk Medicines, and Finished Drugs. The Intermediates & Bulk Medicines segment engages in the manufacturing and selling of intermediates and bulk medicines. The Finished Drugs segment engages in the manufacturing and selling of antibiotics finished drugs and non-antibiotics finished drugs. The company was founded on December 8, 1995 and is headquartered in Hong Kong.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company